Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411833 | 0.92 | HCRTR2 (0.39) | HCRTR2CCR5RECQLALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL6411826 | 0.92 | HCRTR2 (0.39) | HCRTR2CCR5RECQLALDH1A1KDM4E | |
| SCHEMBL6410514 | 0.90 | MAPT (0.40) | HCRTR2CCR5RECQLALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL6410509 | 0.90 | MAPT (0.40) | HCRTR2CCR5RECQLALDH1A1KDM4E | |
| SCHEMBL6409454 | 0.88 | CCR5 (0.40) | HCRTR2CCR5RECQLALDH1A1KDM4E | |
| SCHEMBL6411012 | 0.88 | HCRTR2 (0.41) | HCRTR2CCR5CYP3A4NAMPTALDH1A1 | |
| SCHEMBL6415531 | 0.88 | HCRTR2 (0.41) | HCRTR2CCR5RECQLALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL6418551 | 0.87 | CCR5 (0.40) | HCRTR2CCR5RECQLALDH1A1KDM4E | |
| SCHEMBL6410431 | 0.87 | CCR5 (0.36) | CCR5 | |
| Hydrochloric Acid SCHEMBL6409210 | 0.87 | HCRTR2 (0.40) | HCRTR2CCR5RECQLALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | HCRTR2 247/4885CCR5 4/4885CYP3A4 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.